Tagged with ACA

Europe Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to carve out a slice of this huge growth market. Those who made a bet on obesity years in advance are…

Hong Kong Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges for companies in Hong Kong and the Greater Bay Area region today; how the city acts as both a point…

Hong Kong Paul Tam, who serves as chair professor & VP at Macau University of Science and Technology as well as emeritus professor and honorary clinical professor of surgery at the University of Hong Kong, has made important contributions to advances in paediatric minimal invasive surgery, genetics, and regenerative medicine of birth…

Hong Kong Malaysian national Jonathan Chin culminated his 20+-year career at Boehringer Ingelheim and became GM of the firm’s Hong Kong and Macau affiliate in 2022. He explains his career path through multiple international roles, the shift arising from COVID-19 in Southeast Asia and China, as well as the characteristics of the…

Switzerland This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some of its most exciting companies. Download here.   2020 stands out as having been the best year yet for Swiss…

Switzerland Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.…

Hungary Dr. György Bagdy, professor and former vice rector at Semmelweis University, shares his insights on the longstanding history of pharmacology in Hungary, the key strengths of the country in the field of neuroscience, and the future outlook of a more collaborative and innovation-focused research landscape.   Hungary has the knowledge…

Puerto Rico David Fuster, plant manager of the Dorado factory of Chinese pharma outfit PuraCap, shares the company’s strategy behind the investment in Puerto Rico and how the PuraCap Caribe is leveraging technologies at the facility for new product development. He underlines the importance of Puerto Rico as a manufacturing location for…

Taiwan Nick Lee, general manager of Ipsen Taiwan, Hong Kong, and Macau, shares his journey of building up the affiliate after having separated from their local partner two years ago. Lee also highlights Ipsen’s dedication to Taiwan’s healthcare system by introducing innovative products in its key areas of oncology, neurology, and…

Taiwan Dr Fu-Tong Liu, vice president of Academia Sinica, introduces the institution and its research mission of promoting basic research and enhancing translation. Dr Liu goes on to describe Academia Sinica’s biomedical research environment and also highlights the new National Biotechnology Research Park which will have a vital role in developing…

Hong Kong Frederic Charles, CEO of Pierre Fabre Hong Kong and Macau, outlines brand perceptions of Pierre Fabre’s dermatological products in Hong Kong, e-commerce, and other emerging skincare trends in Asia.   With the opening of Pierre Fabre Hong Kong affiliate in 2016, what were the main achievements so far? The affiliate…

AstraZeneca Gwenael Meneux of AstraZeneca Hong Kong and Macau gives his initial impression of the HK market, outlines his unusual career trajectory and the new innovations AZ is looking to bring to patients in the region.   Gwenael, you have a very interesting and diverse background that is a bit atypical…